Prothena price target lowered to $43 from $60 at RBC Capital

RBC Capital lowered the firm’s price target on Prothena (PRTA) to $43 from $60 and keeps a Sector Perform rating on the shares. With Biogen (BIIB) /Eisai’s (ESAIY) subQ lecanemab data initially demonstrating 52% plaque reductions with 17%-22% ARIA, the bar is likely to be higher for a positive Street reaction than it was prior to Prothena’s initial results, the analyst tells investors in a research note.